ELISA-Based Quantification of p105 (c- erbB-2, HER2/neu) in Serum of Ovarian Carcinoma

Meden, Harald; Fattahi-Meibodi, A; Marx, D

doi:10.1385/1-59259-071-3:125

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amplification of Her2/neu has been found in several human cancers, including ovarian carcinoma. In ovarian cancer, 9% to 38% of patients have increased levels of p105, the shed extracellular domain of the HER-2/neu protein (493)(494)(495). According to one report, measurement of Her2/neu alone or in combination with CA125 is not useful for differentiating benign from malignant ovarian tumors (495 ).…”

Section: Pai-1 and Pai-2mentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

show abstract

Section: Pai-1 and Pai-2mentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

View full text Add to dashboard Cite

show abstract

“…29 Conventional methods of p105 (ECD) quantitation are well described and usually involve the technique of enzyme-linked immunosorbent assay (ELISA). [30][31][32][33][34] The use of SPR spectroscopy for detection and quantification of a particular bioanalyte is accomplished through signal transduction associated with antibody-antigen, Ab-Ag, pairing. For our work, this requires a suitable biosensor that incorporates a receptor antibody capable of capturing either the p185 HER-2 or the p105 HER-2 ligand antigen.…”

Section: Introductionmentioning

confidence: 99%

Surface Plasmon Resonance Investigations of Human Epidermal Growth Factor Receptor 2

et al. 2006

View full text Add to dashboard Cite

This investigation utilizes surface plasmon resonance (SPR) spectroscopy to detect and quantify human epidermal growth factor receptor 2 (HER-2), an oncogene product that is over-expressed in some aggressive forms of breast cancer. Specifically, the HER-2 trans-membrane protein p185 and its extra cellular fragment p105 are analytes targeted in this work by using a gold-based biosensor slide on which an anti-HER-2 antibody has been immobilized by attachment to Protein G that is fixed to the gold film. A detection limit of > or =11 ng/mL for p185 resulted when trastuzumab was used as the anti-HER-2 antibody on the biosensor slide. Experiments with semi-purified p105 revealed that it binds weakly and reversibly to trastuzumab, therefore complicating its detection and quantification. Results of studies that reacted a 13-amino-acid peptide (PP13) from the HER-2 kinase domain with its specific antibody were critically different than p185 and p105 studies. Spectral analysis of the reflectivity at constant bulk buffer refractive index revealed a progressive negative SPR shift over time. A negative shift suggests that a loss of protein mass from the anti-PP13 antibody-Protein G biosensor is occurring. Several possibilities that may explain these negative SPR shifts are discussed.

show abstract

Dysregulation of circulating sTie2 and sHER2 in HIV-infected women with preeclampsia

Mazibuko

Moodley

Naicker

2019

Hypertension in Pregnancy

View full text Add to dashboard Cite

ELISA-Based Quantification of p105 (c- erbB-2, HER2/neu) in Serum of Ovarian Carcinoma

Cited by 3 publications

References 8 publications

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Surface Plasmon Resonance Investigations of Human Epidermal Growth Factor Receptor 2

Dysregulation of circulating sTie2 and sHER2 in HIV-infected women with preeclampsia

Contact Info

Product

Resources

About